140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
Journal
Journal of Thoracic Oncology
Journal Volume
11
Journal Issue
4
Pages
S117-S118
Date Issued
2016
Author(s)
SDGs
Other Subjects
afatinib; alanine aminotransferase; epidermal growth factor receptor; gefitinib; acne; advanced cancer; alanine aminotransferase blood level; Article; Asian; brain metastasis; controlled study; diarrhea; drug efficacy; drug response; drug safety; drug treatment failure; drug withdrawal; EGFR gene; female; gene deletion; gene mutation; human; major clinical study; male; non small cell lung cancer; open study; overall survival; phase 2 clinical trial; priority journal; progression free survival; prospective study; randomized controlled trial; rash; side effect; tumor volume
Publisher
Elsevier Inc
Type
journal article